Noriyuki Abe

Appendix 4C Quarterly Activity Report

Retrieved on: 
Tuesday, January 31, 2023
Survival, LVAD, Regenerative medicine, Mesoblast, MSB, Inflammation, Center for International Blood and Marrow Transplant Research, MOA, Oaktree Capital Management, Biologics license application, BLA, Degenerative disc disease, Patient, BAT, FDA, Heart, Appendix, MESO, Noriyuki Abe, Executive, Pain, Mobile phone, Video game, Pharmaceutical industry, Fine chemical

NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2022.

Key Points: 
  • NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2022.
  • Long-term survival results were received for remestemcel-L from Mesoblast’s pivotal Phase 3 clinical trial (GVHD-001) in children with SR-aGVHD.
  • These new long-term survival data are a key component of the Company’s BLA resubmission to the FDA.
  • Salary payments to full-time Executive Directors were US$324,678 and fees to Non-Executive Directors were US$192,164, detailed in Item 6 of the Appendix 4C cash flow report for the quarter.9

Rights and Issues Investment Trust PLC: Directorate Change

Retrieved on: 
Sunday, December 18, 2022
Aurora, Trust, University of Leicester, Accounting, Listing Rules, Business, Audit, Noriyuki Abe, Risk, Growth, Chartered accountant, University, Financial adviser, Honours degree

Rights and Issues Investment Trust PLC: Directorate Change

Key Points: 
  • Rights and Issues Investment Trust PLC: Directorate Change
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The Board of Rights and Issues Investment Trust PLC (the “Company”) is pleased to announce the intention to appoint Helen Vaughan as a Non-Executive Director and Chair of the Audit, Risk and Compliance Committee with effect from 1 January 2023.
  • She currently serves as a non-executive director on three Irish fund boards, an Irish and UK management company and a UK investment trust which has not yet listed.
  • Helen is also the chair of the audit committee for Aurora Investment Trust PLC.

Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022

Retrieved on: 
Sunday, October 30, 2022
Transplant, EAP, MESO, Inflammation, GLOBE, Director, Mesoblast, Chief, MACE, MSB, Private Securities Litigation Reform Act, GVHD, Company, BLA, FDA, Executive, Patient, Fast track (FDA), IND, Industry, Australian Securities Exchange, Death, Mostafa Rashidi Suja, Heart, ASX, Survival, SEC, Noriyuki Abe, Appendix, Policy, Investigational New Drug, LVEF, Pediatric Transplantation, Forward-looking statement, Pain, McMillan, Marketing, LVAD, Regenerative medicine, Hematopoietic stem cell transplantation, MOA, Risk, Immune system, Technology, Pharmaceutical industry, Birth control, Dietary supplement, Medical imaging, Management, Cryptocurrency

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30, 2022.

Key Points: 
  • NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30, 2022.
  • The Company plans to have clearance from the FDA by year-end 2022 for the pivotal trial with primary endpoint 12-month reduction in pain.
  • Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets.
  • Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms.

ENDEAVOUR ANNOUNCES APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Retrieved on: 
Thursday, September 29, 2022
UK Corporate Governance Code, World Gold Council, General counsel, ESG, TSX, Chairperson, LBMA, GBI, London School of Economics, Senior, Compliance, Corporate governance in the United Kingdom, London Bullion Market Association, Oversight Committee, Industry, OTCQX, LSE, Gold bar, CEO, Chair, Sustainability Accounting Standards Board, Board, Noriyuki Abe, IETF Administrative Oversight Committee, Management, Economics

London, 29 September 2022 Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) (Endeavour or the Company) is pleased to announce the appointment of Sakhila Mirza to the Board as an Independent Non-Executive Director, effective today.

Key Points: 
  • London, 29 September 2022 Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) (Endeavour or the Company) is pleased to announce the appointment of Sakhila Mirza to the Board as an Independent Non-Executive Director, effective today.
  • Sakhila Mirza is currently General Counsel andan Executive Director of the Board of the London Bullion Market Association (LBMA), leading their sustainability, responsible sourcing and ESG agenda.
  • The Chair, Srinivasan Venkatakrishnan, was considered independent at the time of his appointment.
  • In addition, James Askew and Naguib Sawiris serve as Non-Executive Directors, alongside Sbastien de Montessus as Executive Director, President and CEO.

Universal Music Group N.V. Announces Results of its 2022 Annual General Meeting of Shareholders

Retrieved on: 
Thursday, May 12, 2022
Entrepreneurship, Company, Arthur Young (accountant), EUR, Music, Director, AGM, UMG, Culture, LLP, Noriyuki Abe, Universal Music Group, Sherry Lansing, Annual general meeting, Adoption, Holding company

HILVERSUM, Netherlands, May 12, 2022 /PRNewswire/ -- Universal Music Group N.V. ("UMG" or "the Company") today announced the results of its first-ever Annual General Meeting of shareholders ("AGM") held earlier today.

Key Points: 
  • HILVERSUM, Netherlands, May 12, 2022 /PRNewswire/ -- Universal Music Group N.V. ("UMG" or "the Company") today announced the results of its first-ever Annual General Meeting of shareholders ("AGM") held earlier today.
  • At Universal Music Group (EURONEXT: UMG), we exist to shape culture through the power of artistry.
  • UMG is the world leader in music-based entertainment, with a broad array of businesses engaged in recorded music, music publishing, merchandising and audiovisual content.
  • For more information on Universal Music Group N.V. visit www.universalmusic.com .

Universal Music Group N.V. Announces Results of its 2022 Annual General Meeting of Shareholders

Retrieved on: 
Thursday, May 12, 2022
Entrepreneurship, Company, Arthur Young (accountant), EUR, Music, Director, AGM, UMG, Culture, LLP, Noriyuki Abe, Universal Music Group, Sherry Lansing, Annual general meeting, Adoption, Holding company

HILVERSUM, Netherlands, May 12, 2022 /PRNewswire/ -- Universal Music Group N.V. ("UMG" or "the Company") today announced the results of its first-ever Annual General Meeting of shareholders ("AGM") held earlier today.

Key Points: 
  • HILVERSUM, Netherlands, May 12, 2022 /PRNewswire/ -- Universal Music Group N.V. ("UMG" or "the Company") today announced the results of its first-ever Annual General Meeting of shareholders ("AGM") held earlier today.
  • At Universal Music Group (EURONEXT: UMG), we exist to shape culture through the power of artistry.
  • UMG is the world leader in music-based entertainment, with a broad array of businesses engaged in recorded music, music publishing, merchandising and audiovisual content.
  • For more information on Universal Music Group N.V. visit www.universalmusic.com .

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022

Retrieved on: 
Wednesday, May 11, 2022
Board, Corporate communication, Noriyuki Abe, Board of directors, AD, University, MRCP, Institute of technology, University of Sheffield, Company, Merck Serono, Merck, Euronext Amsterdam, Gutjahr, Patient, Fibrosis, Doctor of Philosophy, Risk, Initial public offering, AGM, Cancer, Deutsche Bank, MD, Neurology, CEST, MorphoSys, I due gattoni a nove code... e mezza ad Amsterdam, MBA, Annual general meeting, News, Protein, Inflammation, Biology, Growth, Head, Therapy, Medical device, Security (finance), Management, Pharmaceutical industry, Nasdaq, Novartis

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022 (news with additional features)

Key Points: 
  • Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022 (news with additional features)
    The issuer is solely responsible for the content of this announcement.
  • In line with the Companys commitment to meet international best practice standards, Vivoryon proposes to appoint two additional Non-Executive Directors to its Board of Directors.
  • Dr. Riedls broad expertise also includes senior advisory roles in a number of IPOs and financings in various geographies.
  • Certain risk factors that may affect the Companys future financial results are discussed in the published annual financial statements of the Company.

Falcon Oil & Gas Ltd. - Board Changes

Retrieved on: 
Tuesday, May 3, 2022
Board, Beetaloo, Noriyuki Abe, Company, Canadian Society of Petroleum Geologists, PricewaterhouseCoopers, University, AIM, Senior, Chartered accountant, Â, AAPG, Moses Austin, Time, Adobe Inc., Joachim, CFO, Petroleum, Association, Heytesbury Pty. Ltd., American Association, Knowledge, Burlington Resources, The Elements of Style, Chesapeake Energy, Key Stage 3, Exxon, FOG, VP, Management

03 May 2022 - Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) is pleased to confirm the appointment of Tom Layman as a Non-Executive Director and to the Board of the Company (the Board).

Key Points: 
  • 03 May 2022 - Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) is pleased to confirm the appointment of Tom Layman as a Non-Executive Director and to the Board of the Company (the Board).
  • In conjunction with these appointments, Daryl Gilbert and JoAchim Conrad have retired as Non-Executive Directors from the Board.
  • Tom Layman is a certified petroleum geologist with over 40 years experience in the oil and gas industry.
  • Falcon Exploration And Production South Africa (Pty) Ltd.
    At the date of this announcement,Anne Flynnholds 200,000 ordinary shares in the capital of the Company.

Surge Copper Announces Annual Grant of Equity Incentive Awards

Retrieved on: 
Tuesday, January 25, 2022
SURG, Copper, Silver, Gold, GLOBE, Noriyuki Abe, Molybdenum, Consultant, Imperial Metals, Company, Berg, TSX Venture Exchange, Measurement, Centerra Gold, Mining, Ootsa Lake Formation

A further portion of the restricted share units will vest annually over a three-year period from the award date.

Key Points: 
  • A further portion of the restricted share units will vest annually over a three-year period from the award date.
  • A further portion of the restricted share units was granted to Non-Executive Directors and will vest upon their departure from the Company.
  • Berg contains pit constrained 43-101 compliant resources of copper, molybdenum, and silver in the Measured and Indicated categories.
  • Combined, the adjacent Ootsa and Berg properties give Surge a dominant land position in the Ootsa-Huckleberry-Berg district and control over four advanced porphyry deposits.

Hibernia appoints Non-Executive Directors

Retrieved on: 
Thursday, November 25, 2021
DCC, Chartered Accountants Ireland, Financial Conduct Authority, Ireland, Allied Irish Banks, Retirement, Partner, DCC plc, KPMG, Noriyuki Abe, Security (finance), Animal, Management

Hibernia REIT plc ("Hibernia") announces the appointment of two Non-Executive Directors with effect from 25 November 2021.

Key Points: 
  • Hibernia REIT plc ("Hibernia") announces the appointment of two Non-Executive Directors with effect from 25 November 2021.
  • Mr. Fergal O'Dwyer retired as Chief Financial Officer and Executive Director of DCC plc in July 2020.
  • He was a Partner in KPMG from 2002 until his retirement and was President of Chartered Accountants Ireland in 2020.
  • Hibernia confirms that no other information is required to be disclosed pursuant to paragraph 6.1.66 of the Listing Rules of Euronext Dublin and paragraph 9.6.13 of the Listing Rules of the Financial Conduct Authority.